Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.

TRE-515 could improve the durability of response in combination with KRAS inhibition in patients with advanced non–small cell lung cancer, investigators stated.

FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.

Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.

Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.

Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.

The MUC16xCD3 bispecific antibody showed a 73% response rate in phase 1/2 trial; the sponsor announced plans for a potential registrational cohort and phase 3 trial.

Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.